Recent Updates
Recently added Catalysts
BMGL Neutral Sentiment

Basel to Effect Reverse Share Split on June 22, 2026

Key Takeaway: Basel Medical Group Ltd (BMGL) has announced a reverse share split effective June 22, 2026, at a 1-for-12 ratio to comply with Nasdaq Marketplace Rule. This consolidation will automatically convert every 12 ordinary shares into one, reducing the total from approximately 18.8 million to about 1.6 million shares. No shareholder approval is required for this action, which is designed to help maintain a minimum bid price of $1 per share post-split. The adjusted shares will continue trading under the same Nasdaq symbol, BMGL, although the CUSIP number will change.
Price reaction · baseline $7.656 (2026-06-09 close) · hit after-hours · clean, no other BMGL news in the window
day 0 close
-8%
day 1
-9.4%
day 3
-4.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Reverse share split may help comply with Nasdaq listing requirements.
  • No shareholder approval needed simplifies the process.
  • Reduces the total number of shares, potentially increasing per-share value.

CONCERNS & RISKS

  • Share price must rise above $1 post-split to maintain listing.
  • Significant dilution of shares can be concerning for current shareholders.

Full Press Release Details

to Effect Reverse Share Split on June 22, 2026
June 10, 2026 (GLOBE NEWSWIRE) - Basel Medical Group Ltd (Nasdaq: BMGL) (the "Company"), a medical clinic operator
in Singapore, today announced that the Company's board of directors has approved the consolidation of the Company's issued
and outstanding shares of the Company on a 1-for-12 ratio with the marketplace effective date of June 22, 2026.
objective of the reverse share split is to enable the Company to recomply with Nasdaq Marketplace Rule 5550(a)(2), which requires listed
securities to maintain a minimum bid price of $1 per share. According to the law of the British Virgin Islands, the jurisdiction of the
Company's incorporation, and its memorandum and articles of association, no approval by shareholders and no amendment of the Company's
articles of association will be required for the reverse share split.
with the opening of trading on June 22, 2026, the Company's ordinary shares which have no par value will trade on the Nasdaq Capital
Market on a split-adjusted basis, under the same symbol "BMGL" but with a new CUSIP number, G0864B111.
a result of the reverse share split, every 12 ordinary shares outstanding will automatically combine and convert to one issued and outstanding
ordinary share without any action required on the part of the shareholders. The number of issued and outstanding ordinary shares of the
Company will be correspondingly reduced from 18,785,750 (based on the number of shares outstanding as of June 10, 2026) to approximately
1,565,480, subject to adjustment for rounding. No fractional shares will be issued to any shareholders in connection with the reverse
share split, and each shareholder will be entitled to receive one whole ordinary share of the Company in lieu of the fractional share
that would have resulted from the reverse share split.
Basel Medical Group Ltd
Medical is a Singapore-based provider of orthopedic and trauma services, sports medicine, orthopedic procedures and surgery, as well
as neurosurgical treatments, executive health screening services, occupational medicine, rehabilitation, mental and women's health
and general medical practices. Our operations are based in Singapore, with our clinics being located at Suntec City Mall, Macpherson
Road, Toa Payoh, Margaret Drive, Tampines, Gateway East and Gleneagles Medical Centre. Over the last 20 years, our group has forged strong
and lasting relationships with a large base of corporations, particularly those in the construction, marine and oil & gas industries,
which underpin our robust business model. As an medical service provider in Singapore with a track record of over 20 years, we are well-positioned
to ride the wave of growth opportunities in the private healthcare industry in Singapore and across Southeast Asia driven by ageing populations,
rising income levels, increasing private insurance coverage, increasing expenditure on healthcare, growing sports participation rate
and Singapore's position as a premium destination for healthcare services in Asia. Our management and medical practitioner team
comprises a roster of orthopedic and neurosurgery specialists, general practitioners, corporate finance and healthcare partnership specialists.
Basel Medical Group Ltd serves as the holding company of our group and we conduct our operations through our operating subsidiaries based
in Singapore. For more information, please visit the Company's website: www.baselmedical.com.
investor and media inquiries, please contact:

Frequently Asked Questions

What is the reverse share split ratio for Basel Medical Group Ltd?

The reverse share split will occur at a 1-for-12 ratio.

When will Basel Medical Group's reverse share split take effect?

The reverse share split will take effect on June 22, 2026.

Will shareholders need to take action for the reverse split?

No action is required from shareholders for the reverse share split.

What will happen to ordinary shares after the split?

Twelve ordinary shares will convert to one issued and outstanding share.

Will fractional shares be issued post-reverse split?

No fractional shares will be issued; shareholders receive whole shares instead.

Last updated: Jun 10, 2026